Abstract
De-Escalation of Anti-CD20 Monoclonal Antibodies to Low-Moderate Efficacy Disease-Modifying Treatments in Patients with Relapse-Remitting Multiple Sclerosis: The Initial Iranian Experience
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have